other news related to the 340B drug pricing program,
the House Energy and Commerce Subcommittee on Health hosted a hearing last week
that examined more than a dozen legislative proposals that would make changes
to the program. The proposals included language that would void recent
outpatient prospective payment system changes in the payment amount for certain
drugs and biologicals purchased under the program (H.R. 4392); limit the orphan
drug exclusion (H.R. 2889); establish a moratorium on the registration of
certain new 340B hospitals and associated sites (H.R. 4710); require certain
disproportionate share hospitals to submit reports on low-income use of
outpatient hospital services (H.R. 5598); clarify the intent of the program and
enhance program integrity (H.R. 6071); and provide for certain user fees (H.R.
6240), among other proposals. Read more in IHA's Federal Update.